Results 31 to 40 of about 149,549 (197)
An escherichia coli vaccine co-expressing listeriolysin-O and tumour antigen in cancer immunotherapy and the mechanisms of immune regulation [PDF]
, 2009 PhDSome recombinant bacterial strains have been shown to be very efficient in experimental therapies against cancer in rodent models. Amongst them is an E. coli that expresses the Listeriolysin-O protein (LLO) and a model tumour antigen ovalbumin (OVA)
Dai, Ming-Shen
core +4 more sources
Frontiers in Oncology, 2022 Breast cancer is the most common non-cutaneous cancer affecting women worldwide and is a major cause of cancer-related morbidity and mortality in females.
Ashley Drohan +4 more
doaj +1 more source
Frontiers in Immunology, 2021 Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer worldwide, with ever increasing incidence and mortality. While most patients can be treated successfully with surgical excision, cryotherapy, or radiation therapy,
Dejan Vidovic +7 more
doaj +1 more source
, 2022 A considerable amount of melanoma patients show primary resistance to PD-1 and CTLA-4 inhibitors. We have previously reported a beneficial role of intralesional Interleukin-2 (IL-2) in 9 melanoma patients developing new locoregional metastases under ...
Behrens, Max +7 more
core +1 more source
The role of intralesional immunotherapy in Condyloma Acuminata
World Journal of Advanced Research and Reviews, 2023 Intralesional immunotherapy is one of the immunotherapy modalities that can be given to patients with condyloma acuminata (CA) with a high success rate both in inhibiting progression and preventing recurrence of genital warts. Intralesional immunotherapy regimens that are currently being studied are the use of vaccines and cytokines.
Lita Setyowatie +1 more
openaire +2 more sources
Immunotherapy with Intralesional Candida Albicans Antigen in Plane Warts
SVU - International Journal of Medical Sciences, 2023 Background: Warts are a frequent skin condition. Human papillomavirus is the culprit (HPV). One of the warts treatments is intralesional immunotherapy utilizing the Candida antigen. Objectives: To evaluate the efficacy of candida antigen in treatment of
Hassan Mohammed Ibrahim +3 more
doaj +1 more source
, 2019 Treatment of genital warts using intralesional immunotherapy has been recently investigated in a few studies and showed promising efficacy and safety, and low recurrence rates as compared to traditional ablative therapies.
Nofal, A
core +3 more sources
Intralesional Treatments for Invasive Cutaneous Squamous Cell Carcinoma
, 2023 Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans and has the potential to progress locally, metastasize, and cause death in a subset of patients.
Cañueto, Javier +3 more
core +1 more source
Intralesional antigen immunotherapy for warts in the era of COVID-19 [PDF]
Journal of Dermatological Treatment, 2020 To the editor, COVID-19 infection is an emerging pandemic disease caused by the novel coronavirus SARS-CoV-2 that was first isolated from patients with severe pneumonia in Wuhan, China in December ...
Nofal, Ahmad +3 more
openaire +2 more sources
Treatment of Multiple Common Warts by Intralesional Immunotherapy: Review Article [PDF]
, 2022 Background: Human papillomavirus (HPV) is the most prevalent cause of warts on the skin and mucous membranes of the human body. With the aid of a variety of destructive and immunotherapeutic methods, wart therapy remains a major difficulty.
Nofal, Ahmad Abd Elgawad +2 more
core